Clinical trialNCT05332002RecruitingPhase 2Interventional

sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)

SponsorRutgers, The State University of New JerseyEnrollment38Gastro-Intestinal Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The primary objective is to determine the clinical efficacy of treatment regimen in terms of objective response rate (ORR). The secondary objectives is to determine the clinical efficacy of the study treatment in terms of progression free survival (PFS) and overall survival (OS). Additionally, to characterize the safety and toxicity profile of the study treatment as measured by the adverse event rates.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Patrick Boland, MD
Rutgers Cancer Institute of New Jersey
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Rwjbarnabas Health - Robert Wood Johnson University Hospital
Hamilton, New Jersey, United States
Recruiting
Rwjbarnabas Health - Monmouth Medical Center Southern Campus
Lakewood, New Jersey, United States
Recruiting
Rwjbarnabas Health - Monmouth Medical Center
Long Branch, New Jersey, United States
Recruiting
Rwjbarnabas Health - Robert Wood Johnson University Hospital, Somerset
New Brunswick, New Jersey, United States
Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Recruiting
Rwjbarnabas Health - Newark Beth Israel Medical Center
Newark, New Jersey, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Four week alternating FOLFOX and FOLFIRI

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 13 Jul 2022
Primary completion: 1 Aug 2026
Completion: 1 Aug 2026
Last update posted: 7 Jan 2026
Registered enrollment: 38
Registry id: NCT05332002

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.